Immunohistochemical study of DNA topoisomerase II in human gastric disorders

American Journal of Pathology

Volumn 149, Issue 3, 1996, Pages 997-1007

  Yabuki, Noritaka ^a   Sasano, Hironobu ^a   Kato, Katsuaki ^a   Ohara, Shuichi ^a   Toyota, Takayosi ^a   Nagura, Hiroshi ^a   Miyaike, Mitsuko ^b   Nozaki, Naohito ^b   Kikuchi, Akihiko ^b  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Mitsubishi Kagaku Institute of Life Sciences   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); TUMOR ANTIGEN;

ADENOMA; ARTICLE; CELL CYCLE; CONTROLLED STUDY; FLOW CYTOMETRY; FROZEN SECTION; HUMAN; HUMAN TISSUE; LABELING INDEX; PRIORITY JOURNAL; PROTEIN LOCALIZATION; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH MUCOSA;

ADENOCARCINOMA; ADENOMA; AGED; ANTIGENS, NEOPLASM; DNA TOPOISOMERASES, TYPE II; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; STOMACH; STOMACH NEOPLASMS;

EID: 0029748329     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Quinn CM, Wright NA: The clinical assessment of proliferation and growth in human tumours: evaluation of methods and applications as prognostic variables. J Pathol 1990, 160:93-102
2. Gratzner HG: Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: a new reagent for detection of DNA replication. Science 1982, 218:474-475
3. Itakura Y, Sasano H, Mori S, Nagura H: DNA ploidy in human esophageal squamous dysplasia and squamous cell carcinoma as determined by image analysis. Mod Pathol 1984, 7:867-873
4. Coon JS, Landay AL, Weinstein RS: Advances in flow cytometry for diagnostic pathology. Lab Invest 1987, 57:453-479
5. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA: Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 1983, 31:1333-1335
6. Gerdes J, Schwab U, Lemke H, Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983, 31:13-20
7. Waseem NH, Lane DP: Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA): structural conservation and the detection of a nucleolar form. J Cell Sci 1990, 96:121-129
8. Schluter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD, Gerdes J: The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 1993, 123:513-522
9. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984, 133:1710-1715
10. Sasano H, Imatani A, Shizawa S, Suzuki T, Nagura H: Cell proliferation and apotosis in normal and pathologic human adrenal. Mod Pathol 1995, 8:11-17
11. 2+ transients are not required for platelet-derived growth factor to induce cell cycle progression of vascular smooth muscle cells in primary culture: actions of tyrosine kinase. J Biol Chem 1994, 269:9011-9018
12. Schwarting R: Little missed markers and Ki-67. Lab Invest 1993, 68:597-599
13. Uemura T, Ohkura H, Adachi Y, Morino K, Shiozaki K, Yanagida M: DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe. Cell 1987, 50:917-925
14. Heck MM, Hittelman WN, Earnshaw WC: Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci USA 1988, 85:1086-1090
15. Hsiang YH, Wu HY, Liu LF: Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res 1988, 48:3230-3235
16. Hwang JL, Shyy SH, Chen AY, Juan CC, Whang PJ: Studies of topoisomerase-specific antitumor drugs in human lymphocytes using rabbit antisera against recombinant human topoisomerase II polypeptide. Cancer Res 1989, 49:958-962
17. Kaufmann SH, McLaughlin SJ, Kastan MB, Liu LF, Karp JE, Burke PJ: Topoisomerase II levels during granulocytic maturation in vitro and in vivo. Cancer Res 1991, 51:3534-3543
18. Schneider E, Hsiang YH, Liu LF: DNA topoisomerases as anticancer drug targets. Adv Pharmacol 1990, 21: 149-183
19. Liu LF: DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989, 58:351-375
20. Kasahara K, Fujiwara Y, Sugimoto Y, Nishio K, Tamura T, Matsuda T, Saijo N: Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines. J Natl Cancer Inst 1992, 84:113-118
21. Kim R, Hirabayashi N, Nishiyama M, Saeki S, Toge T, Okada K: Expression of MDR1, GST-pi and topoisomerase II as an indicator of clinical response to adriamycin. Anticancer Res 1991, 11:429-431
22. Nitiss JL, Liu YX, Harbury P, Jannatipour M, Wasserman R, Wang JC: Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. Cancer Res 1992, 52:4467-4472
23. Prosperi E, Sala E, Negri C, Oliani C, Supino R, Astraldi RG, Bottiroli G: Topoisomerase IIα and -β in human tumor cells grown in vitro and in vivo. Anticancer Res 1992, 12:2093-2099
24. Sullivan DM, Glisson BS, Hodges PK, Smallwood KS, Ross WE: Proliferation dependence of topoisomerase II mediated drug action. Biochemistry 1986, 25:2248-2256
25. Sullivan DM, Latham MD, Ross WE: Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells. Cancer Res 1987, 47:3973-3979
26. Webb CD, Latham MD, Lock RB, Sullivan DM: Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line. Cancer Res 1991, 51:6543-6549
27. Lauren P: The two histological main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma. Acta Pathol Microbiol Scand A 1965, 64:31-49
28. Kimura K, Nozaki N, Saijo M, Kikuchi A, Ui M, Enomoto T: Identification of the nature of modification that causes the shift of DNA topoisomerase IIβ to apparent higher molecular weight forms in the M phase. J Biol Chem 1994, 269:24523-24526
29. Sasano H, Miyazaki S, Goukon Y, Nishihira T, Sawai T, Nagura H: Expression of p53 in human esophageal carcinoma. Hum Pathol 1992, 23:1238-1243
30. Goukon Y, Sasano H, Nishihira T, Nagura H, Mori S: p53 overexpression in human esophageal carcinoma: a correlation with tumor DNA ploidy and two parameter flow cytometric study. Anticancer Res 1994, 14:1305-1312
31. Schneider U, Schwenk HU, Bornkamm G: Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int J Cancer 1977, 19:521-526
32. Katoh R, Bray CE, Suzuki K, Komiyama A, Hemmi A, Kawaoi A, Oyama T, Sugai T, Sasou S: Growth activity in hyperplastic and neoplastic human thyroid determined by an immunohistochemical staining procedure using monoclonal antibody MIB-1. Hum Pathol 1995, 26:139-146
33. Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST, Mirabelli CK: Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 1989, 28:8154-8160
34. Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, Masters JR, Hickson ID: Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 1991, 51:6592-6595
35. Drake FH, Zimmerman JP, McCabe FL, Bartus HF, Per SR, Sullivan DM, Ross WE, Mattern MR, Johnson RK, Crooke ST, Mirabelli CK: Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells: evidence for two forms of the enzyme. J Biol Chem 1987, 262:16739-16747
36. Hall PA, Levison DA, Woods AL, Yu CC, Kellock DB, Watkins JA, Barnes DM, Gillett CE, Camplejohn R, Dover R, Waseem NH, Lane DP: Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990, 162:285-294
37. Yonemura Y, Ooyama S, Sugiyama K, Ninomiya I, Kamata T, Yamaguchi A, Matsumoto H, Miyazaki I: Growth fractions in gastric carcinomas determined with monoclonal antibody Ki-67. Cancer 1990, 65:1130-1134
38. Oya M, Yao T, Nagai E, Tsuneyoshi M: Metastasizing intramucosal gastric carcinomas: well differentiated type and proliferative activity using proliferative cell nuclear antigen and Ki-67. Cancer 1995, 75:926-935
39. Fogt F, Gibbons D, Hallgrimsson J, Holden J, Alder SL, O'Brien MJ: Comparison of topoisomerase II α and MIB1 expression in benign, dysplastic, and malignant gastric mucosal biopsies Mod Pathol 1996, 9:63A
40. Giaccone G, Gazdar AF, Beck H, Zunino F, Capranico G: Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res 1992, 52:1666-1674
41. Binaschi M, Capranico G, De IP, Mariani M, Supino R, Tinelli S, Zunino F: Comparison of DNA cleavage induced by etoposide and doxorubicin in two human small-cell lung cancer lines with different sensitivities to topoisomerase II inhibitors. Int J Cancer 1990, 45:347-352
42. Smith PJ, Morgan SA, Fox ME, Watson JV: Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells. Biochem Pharmacol 1990, 40:2069-2078
43. van der Zee AG, Hollema H, de Jong S, Boonstra H, Gouw A, Willemse PH, Zijlstra JG, de VE: P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res 1991, 51: 5915-5920